PD-1 and PD-L1 Inhibitors Market by Application and Geography - Forecast and Analysis 2021-2025

The PD-1 and PD-L1 inhibitors market share is expected to increase by USD 29.97 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 19.11%.

This PD-1 and PD-L1 inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and ROW). The PD-1 and PD-L1 inhibitors market report also offers information on several market vendors, including Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. among others.

What will the PD-1 and PD-L1 Inhibitors Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the PD-1 and PD-L1 Inhibitors Market Size for the Forecast Period and Other Important Statistics

"The lack of approved therapies for cancer in the past led to a high mortality rate. However, the market has witnessed a significant decrease in mortality rate owing to the increasing approvals of novel cancer therapies in recent years."

PD-1 and PD-L1 Inhibitors Market: Key Drivers and Challenges

The reduction in cancer mortality rate is notably driving the PD-1 and PD-L1 inhibitors market growth, although factors such as the availability of alternative therapies may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the PD-1 and PD-L1 inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key PD-1 and PD-L1 Inhibitors Market Driver

The lack of approved therapies for cancer in the past led to a high mortality rate. However, the market has witnessed a significant decrease in mortality rate owing to the increasing approvals of novel cancer therapies in recent years. While underdeveloped economies such as Niger continue to have high mortality rates, developed countries such as the US, the UK, and Canada have witnessed a significant decrease. The reduction in the mortality rate of cancer is largely due to the availability of novel drugs, including PD-1 and PD-L1 inhibitors. This proven efficacy of the cancer drugs leads to a high patient adherence ratio, thereby driving the market growth. The reducing mortality rates of cancer and the increasing adoption rates of PD-1 and PD-L1 inhibitors are encouraging vendors in the market to spend heavily on research and development (R&D) of novel drugs, which is expected to add significant value to the PD-1 and PD-L1 inhibitors market during the forecast period. 

Key PD-1 and PD-L1 Inhibitors Market Challenge

Despite the proven efficacy of PD-1 and PD-L1 inhibitors in the treatment of various types of solid tumors and blood-related tumors, the market faces a heavy threat from the presence of alternative therapies. The increasing prevalence of cancer has resulted in an urgent need for the development of more advanced therapies to treat these indications. As a result, various vendors have started developing therapies for inhibiting PARP and HER-2. These therapies are called targeted anti-cancer therapies, in which the drug works on inhibiting the growth of the cancer-causing cell in the body. There are multiple targeted therapies approved for the treatment of various types of cancer. The global pharmaceutical market has also witnessed the advent of regenerative therapies such as CAR T-cell therapy and gene therapy for the treatment of cancer. The curative nature of regenerative therapies poses a huge threat to the global PD-1 and PD-L1 inhibitors market, and the expected approval of these therapies during the forecast period is expected to increase the threat, leading to less preference for PD-1 and PD-L1 inhibitors.

This PD-1 and PD-L1 market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Market Overview

The parent market, the global pharmaceuticals market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. 

Who are the Major PD-1 and PD-L1 Inhibitors Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Agenus Inc.
• Amgen Inc.
• AnaptysBio Inc.
• AstraZeneca Plc
• BeiGene Ltd.
• Bristol-Myers Squibb Co.
• Checkpoint Therapeutics Inc.
• F. Hoffmann-La Roche Ltd.
• Merck and Co. Inc.
• Pfizer Inc.

This statistical study of the PD-1 and PD-L1 inhibitors market encompasses successful business strategies deployed by the key vendors. The PD-1 and PD-L1 inhibitors market is fragmented and the vendors are entering into strategic alliances to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The PD-1 and PD-L1 market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for PD-1 and PD-L1 Inhibitors Market?

For more insights on the market share of various regions Request for a FREE sample now!

51% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for PD-1 and PD-L1 inhibitors in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Application Segments in the PD-1 and PD-L1 Inhibitors Market?